Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced updated positive long-term follow-up data from the ...

Nuvation will launch two new studies of safusidenib in glioma, a global pivotal trial and a Phase II trial in the US.

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up New ...

According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.

Global oncology firm Nuvation Bio Inc. NUVB on Monday revealed updated long-term data from a mid-stage trial evaluating ...

This important study provides a mechanistic view of how antibody affinity maturation can reshape encounter-state landscapes and association pathways, with implications for understanding HIV antibody ...

Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte to evaluate additional subcutaneous ...

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets ...

A new peptide-based vaccine elicited antigen-specific T cell responses in high-risk patients, demonstrating proof of concept ...

All three kinesin transport families exhibit unexpectedly slow dissociation under load, explaining robust competition with dynein during bidirectional cargo transport.